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We thank Passaro and colleagues for their interesting simpliﬁed
network meta-analysis, [1] stemming from our recent adjusted
indirect comparison meta-analysis comparing prasugrel versus
ticagrelor in patients with acute coronary syndromes [2].
Indeed, network meta-analyses (i.e. mixed treatment compar-
isons) and adjusted indirect comparisonmeta-analysis are very closely
related, as the latter may be considered a simpliﬁed network meta-
analysis with a star shape [3]. Thus, the fact that Passaro et al. largely
conﬁrm the direction andmagnitude of effect of our own analysis, thus
supporting its precision, accuracy, and validity, comes a no major
surprise, but rather testiﬁes the consistency of these innovative
statistical approaches (Table 1) [4]. We have already endeavored in
this type of research study design in the past, focusing on ﬁrst
generation drug-eluting stents, [5,6] second generation drug-eluting
stents, [7] mechanical coronary recanalization after failed thrombo-
lysis, [8] and antithrombotic agents for atrial ﬁbrillation, [9] and so far
none of our ﬁndings have been disproved by later trials or analyses.
The discrepancy reported by Passero et al. in comparison to our
ﬁndings on the safety end-point of major bleeding (odds ratio 0.70
[95% conﬁdence interval 0.54–0.91] in our work versus risk ratio 0.72
[0.50–1.04] in Passero et al.) might depend more on the deﬁnitions
used than on the statistical method. Indeed, we employed the
stringent albeit insensitive Thrombolysis in Myocardial Infarction
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(TIMI) deﬁnition, and also distinguished coronary artery bypass
grafting (CABG)-related major bleeding from non-CABG-related
major bleeding [2]. Conversely, they did not specify which deﬁnition
was chosen for their analysis, and moreover it is unclear whether they
distinguished CABG-related from non-CABG-related major bleeding
[1]. Thus, we cannot deﬁnitively address the purported discrepancy
between their ﬁndings and our own for major bleeding.
They also appear to have overlooked other key end-points,
including stent thrombosis, which remains in our opinion of utmost
importance, and which appeared signiﬁcantly less likely with
prasugrel than with ticagrelor (odds ratio 0.63 [0.43–0.93],
p_0.020 in our work) [2]. In addition, we could not ﬁnd details on
the statistical methods used to build their analytical network nor the
statistical package employed for computations. We guess they used
Bayesian methods with non-informative priors and the WinBUGS
package, [10] whereas we used ﬁxed-effect frequentist methods and a
freeware package developed by the Meta-analysis and Evidence based
medicine Training in Cardiology (METCARDIO) group [11]. The
aforementioned differences, as well as the simple impact of multiple
testing and the use of risk ratios versus odds ratios might easily
explain apparent discrepancies between the analyses.
In conclusion, we remain positive that advanced statistical
approaches, including adjusted indirect comparison meta-analyses
and mixed treatment comparisons, will play an ever increasing role in
shaping clinical research and practice. Thus, this scholarly debate on
our recent adjusted indirect comparison meta-analysis comparing
prasugrel and ticagrelor in acute coronary syndromes is more than
welcome and stands as further proof of the need for external
repetition and validation of any research endeavor.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing inthe International Journal of
Cardiology (Shewan and Coats 2010;144:1–2).
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Table 1
Comparison of statistical results from Biondi-Zoccai et al.'s adjusted indirect
comparison meta-analysis [2] and Passero et al.'s network meta-analysis [1], both
comparing prasugrel and ticagrelor in patients with acute coronary syndromes.*










OR=1.02 (0.88–1.16) RR=1.04 (0.90–1.19)†
Death OR=0.83 (0.65–1.05) RR=0.82 (0.65–1.04)
Myocardial infarction OR=1.12 (0.94–1.33) NA
Stroke OR=1.18 (0.75–1.81) NA
Stent thrombosis OR=1.59 (1.08–2.32) NA
Major bleeding OR=0.70 (0.54–0.91) RR=0.72 (0.50–1.04)
Major non-CABG-related bleeding OR=0.95 (0.69–1.32) NA
Major CABG bleeding OR=0.23 (0.09–0.58) NA
Major or minor bleeding OR=0.79 (0.65–0.96) NA
Minor bleeding OR=0.93 (0.69–1.27) NA
Drug discontinuation OR=0.98 (0.84–1.13) NA
*Reported with 95% conﬁdence intervals, with valuesb1.0 favoring ticagrelor, and N1.0
favoring prasugrel; †death from cardiovascular causes; CABG = coronary artery bypass
grafting; NA = not available; OR = odds ratio; RR = risk ratio.
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